Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,527 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Saline Clear all
Completed Phase 3 Interventional Results available

Convalescent Plasma in Outpatients With COVID-19

NCT04355767
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma, Saline
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
53
States / cities
Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

NCT02589600
View directory record Official record
Conditions
Osteoporotic Fractures, Osteoporosis, Postmenopausal
Interventions
Zoledronic acid, vitamin D, calcium, Saline
Drug · Dietary Supplement · Other
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Kensington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional

The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke

NCT01088230
View directory record Official record
Conditions
Stroke
Interventions
Botox®, saline solution
Other
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 5, 2026, 5:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

NCT06783309
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions
CNP-103, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
45
States / cities
Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Results available

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

NCT02437487
View directory record Official record
Conditions
Clostridium Difficile
Interventions
SER-109, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Oceanside, California • Sacramento, California • Ventura, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating

NCT01671800
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Type B, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Bivalent-Vaccine Efficacy Study

NCT01609257
View directory record Official record
Conditions
Prevention From Norovirus Infection
Interventions
Norovirus Bivalent Vaccine, Saline Comparator
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly

NCT00333528
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Human butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 5, 2026, 5:45 PM EDT
Active, not recruiting Phase 3 Interventional

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

NCT05345171
View directory record Official record
Conditions
OTC Deficiency
Interventions
DTX301, Placebo, Oral Corticosteroids, Placebo for oral corticosteroids, Sodium Acetate
Genetic · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a

NCT02388009
View directory record Official record
Conditions
Shigellosis
Interventions
Flexyn2a, Placebo, Flexyn2a plus adjuvant
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

NCT02030301
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
VCL-HB01, VCL-HM01, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 5, 2026, 5:45 PM EDT
Withdrawn Phase 2 Interventional

IV Acetaminophen in Children Undergoing Palatoplasty

NCT01760330
View directory record Official record
Conditions
Cleft Palate
Interventions
IV acetaminophen, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 2Phase 3 Interventional

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

NCT00264732
View directory record Official record
Conditions
Uterine Cervical Dysplasia
Interventions
Amolimogene, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
13 Years to 25 Years · Female only
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

NCT01337687
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 5, 2026, 5:45 PM EDT
Terminated Not applicable Interventional Results available

Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

NCT00329732
View directory record Official record
Conditions
Migraine
Interventions
0.5% bupivicaine and 2% lidocaine, Saline placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 5, 2026, 5:45 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

NCT00849667
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 5, 2026, 5:45 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

NCT06810934
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo
Biological
Lead sponsor
Kara Chew
Other
Eligibility
40 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1 Interventional Results available

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

NCT02432716
View directory record Official record
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

NCT02194400
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
RSLV-132
Biological
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Clearwater, Florida • Grand Rapids, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 4 Interventional Results available

Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?

NCT01714336
View directory record Official record
Conditions
Hip Fracture
Interventions
tranexamic acid, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 5, 2026, 5:45 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Prevention of Narcotic-Induced Nausea

NCT00541671
View directory record Official record
Conditions
Nausea
Interventions
Saline, Phenergan
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 3 Interventional Results available

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

NCT02555371
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 100mg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 5, 2026, 5:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

NCT05886777
View directory record Official record
Conditions
Healthy Participants
Interventions
Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
37
States / cities
Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 5, 2026, 5:45 PM EDT